Skip to main content
SpringerLink
Log in
Book cover

Coronary Heart Disease in Clinical Practice pp 107–150Cite as

Coronary Artery Disease

  • Chapter

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ross R. The pathogenesis of atherosclerosis: a prospective of the 1990’s. Nature 1993;362(29):801–809.

    PubMed  CAS  Google Scholar 

  2. Stary HC, Chandler AB, et al. A definition of advanced types of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;5:1355–1374.

    Google Scholar 

  3. Steinberg D, Parthasarathy S, Carew T, et al. Beyond cholesterol: modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989;320:915–924.

    Article  PubMed  CAS  Google Scholar 

  4. Davies MJ. Pathology and morphology of atherosclerosis. Br J Cardiol 1997;4(suppl 1):4–10.

    Google Scholar 

  5. Meir J, Ridker P, Stampher M. Risk factor criterion. Circulation 2004;109(suppl IV):3–5.

    Google Scholar 

  6. Engstrom G, Hedblad B, Staven L. Fatality of future coronary events is related to inflammation-sensitive plasma proteins. Circulation 2004; 110:27–31.

    Article  PubMed  CAS  Google Scholar 

  7. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS) Group. Randomised trial of estrogen plus progestin for secondary prevention of CHD in post menopausakl women. JAMA 1998;280:605–613.

    Article  PubMed  CAS  Google Scholar 

  8. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321–333.

    PubMed  CAS  Google Scholar 

  9. Giuliano F, Leriche A, Jaudinott, et al. Erectile Dysfunction in Patients with Diabetes and/or Hypertension. Rome: ESSIR, 2001.

    Google Scholar 

  10. Billups K, Friedrich S. Assessment of fasting lipid panels and Doppler ultrasound testing in men presenting with erectile dysfunction and no other medical problems. 95th Annual Meeting of the American Urological Association. 2002, Atlanta, GA. Abstract 655.

    Google Scholar 

  11. Pritzker MR. The penile stress test: a window to the heart of man? In 72nd Scientific session of the American Heart Association, 1999, Atlanta.

    Google Scholar 

  12. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between ED and silent myocardial ischaemia in apparently uncomplicated diabetes 2 patients. Circulation 2004;110:22–26.

    Article  PubMed  Google Scholar 

  13. Hacket GI. Impotence—the most neglected complication of diabetes type 2. Diabetes Res 1995;28:75–83.

    Google Scholar 

  14. Klausen IC, Sjol A, Hansen PS, et al. Apolipoprotein (a) isoforms and coronary heart disease in men. A nested case-control study. Atherosclerosis 1997;132:77–84.

    Article  PubMed  CAS  Google Scholar 

  15. Santica M, Marlys L, Koschinsky L. Lipoprotein (a) concentration, apolipoprotein (a) size. Circulation 1999;100:1151–1154.

    Google Scholar 

  16. Carmena R, Duriez P, Fruchart J. Thermogenic lipoprotein particles in atherosclerosis. Circulation 2004;109(suppl 111):2–7.

    Article  CAS  Google Scholar 

  17. Gullette EC, Blumenthat JA, Babyak M, et al. Effects of mental stress on left ventricular and peripheral vascular performance in patients with coronary artery disease. JAMA 1997;277:1521–1526.

    Article  PubMed  CAS  Google Scholar 

  18. Steptoe A. Psychosocial factors in the aetiology of coronary heart disease. Heart J 1999;82:258–259.

    CAS  Google Scholar 

  19. Barefoot JC, Peterson BL, Herrell FE, et al. Type A behavior and survival: a follow-up study of 1,467 patients with coronary artery disease. Am J Cardiol 1989;64;427–432.

    Article  PubMed  CAS  Google Scholar 

  20. Wolf PA, Kannel WB, Sorlie P, et al. Asymptomatic carotid bruit and risk of stroke: the Framingham Study. JAMA 1981;245:1442–1445.

    Article  PubMed  CAS  Google Scholar 

  21. Ridker P, Stampfer M. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481–2485.

    Article  PubMed  CAS  Google Scholar 

  22. Torres JL, Ridker PM. Clinical use of high-sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 2003;18:471–478.

    PubMed  Google Scholar 

  23. Ridker PM, Rifai N, Rose L, et al. Comparison of CRP and LDL-C levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.

    Article  PubMed  CAS  Google Scholar 

  24. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atheromatous event. Circulation 2004;109(suppl IV):6–19.

    Google Scholar 

  25. du Clos TN. Functions of CRP. Ann Med 2000;32:274–278.

    Article  PubMed  Google Scholar 

  26. Ridker PM, Hennekens CH, Roitmann-Johnson B, et al. Plasma concentration of sICAM-1 and risks of future myocardial infarction in apparently healthy men. (US Physician’s Health Study). Lancet 1998;351:88–92.

    Article  PubMed  CAS  Google Scholar 

  27. Wallen NH, Held C, Rehnqvist N, et al. Elevated sICAM-1 and sVCAM-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999; 14:1039–1043.

    Google Scholar 

  28. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(suppl II):2–10.

    Google Scholar 

  29. Ridker PM, Cushman M, Stampher J, et al. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy man. N Engl J Med 1997;336:937–979.

    Article  Google Scholar 

  30. Dichtyl W, Nilsson L, Goncalves L, et al. VLDL activates nuclear factor. KB in endothelial cells. Circulation 1999;845:1085–1094.

    Google Scholar 

  31. Biasucci LM, Liuzzo G, Colizzi C, et al. Clinical use of CRP for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001;2:164–171.

    PubMed  CAS  Google Scholar 

  32. Libby P, Ridker PM. Inflammation and atherosclerosis. Circulation 2002; 105:1135–1143.

    PubMed  CAS  Google Scholar 

  33. Kol A, Bourcier T, Litchman AH, et al. Chlamydial and human heat shock protein 60s active human vascular endothelial, SMCs and macrophages. J Clin Invest 1999;103:571–577.

    Article  PubMed  CAS  Google Scholar 

  34. Gupta S, Leatham EW, Carrington D, et al. Elevated chamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404–407.

    PubMed  CAS  Google Scholar 

  35. Ong G, Tomas BJ, Mansfield AO, et al. Detection and widespread distribution of Chlamydia pneumoniae in the vascular bed and its possible implications. J Clin Pathol 1996;49:102–106.

    PubMed  CAS  Google Scholar 

  36. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammations and the risk of coronary disease. Circulation 2000;101:252–257.

    PubMed  CAS  Google Scholar 

  37. Gibbons GH, Liew C, Goodarzi MO, et al. Genetic markers. Circulation 2004;109(suppl IV):47–58.

    Article  Google Scholar 

  38. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHOAS). Lancet 1996;347:781–786.

    Article  PubMed  CAS  Google Scholar 

  39. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715–1720.

    Article  PubMed  CAS  Google Scholar 

  40. MRC/BHF Heart Protection Study Collaborative Group. Cholesterollowering therapies and antioxidant vitamin supplementation in a wide range of patients at increased risk of CHD death: early safety and efficacy experienced. Eur Heart J 1999;20:725–741.

    Google Scholar 

  41. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the (GISSI-Prevenzione Trial). Lancet 1999;354:447–455.

    Google Scholar 

  42. Yusuf S, Sleight P, Pogue J, et al. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators (HOPE). N Engl J Med 2000;342:145.

    PubMed  CAS  Google Scholar 

  43. Walters DD, Alderman EL, Hsia J, et al. Effects of HRT and antioxidant vitamin supplementation on coronary atherosclerosis in postmenopausal women. JAMA 2002;288:2432–2440.

    Google Scholar 

  44. Brown BG, Zhau XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamin or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1585–1592.

    Article  Google Scholar 

  45. Jacques PF, Boston AG, Wilson PW, et al. Determinants of plasma total homocysteine concentration in Framingham offspring cohort. Am J Clin Nutri 2001;73:613–621.

    CAS  Google Scholar 

  46. Klerk M, Verhoef P, Clarke R, et al. MTHFR 667C→ T polymorphism and risk of CHD: a meta-analysis. JAMA 2002;288:2023–2031.

    Article  PubMed  CAS  Google Scholar 

  47. Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270(22):2726–2727.

    Article  Google Scholar 

  48. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31–62.

    PubMed  CAS  Google Scholar 

  49. Stamfer MJ, Malinow MR, Willer MC, et al. Physicians’ Health Study. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–879.

    Google Scholar 

  50. Wald DS, Law M, Morris JK, et al. Homocystine and cardiovascular disease. BMJ 2002;325:1202.

    PubMed  Google Scholar 

  51. Mennen LI, de Courcy GP, Guilland JC, et al. Homocysteine, cardiovascular factors, and habitual diet in the French supplementation with antioxidant vitamin and mineral study. Am J Clin Nutr 2002;76: 1279–1289.

    PubMed  CAS  Google Scholar 

  52. Homocysteine Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894–898.

    Google Scholar 

  53. Martyn CN, Barker DJP, Osmond C. Mother’s pelvic size, foetal growth, death from stroke and CHD in men in UK. Lancet 1996;348:1264–1268.

    PubMed  CAS  Google Scholar 

  54. Grundy SM, Balady GJ, Criqui M, et al. Primary prevention of CHD guidance from Framingham statement for health care professionals from American Heart Association’s task force on risk reduction. Circulation 1998;97:1876–1887.

    PubMed  CAS  Google Scholar 

  55. The streering committee of the Physician’s Health Study Research group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–135.

    Google Scholar 

  56. Medical Research Council’s general practice research framework. Thrombosis prevention trial. Lancet 1998;351:233–241.

    Google Scholar 

  57. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk. Lancet 2001; 357:89–95.

    Google Scholar 

  58. O’Conner GT, Buring JE, Yusuf S, et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234–244.

    Google Scholar 

  59. Mosca L, Grundy MD, Scott M, et al. AHA/ACC scientific statement. Guide to preventive cardiology for women. Circulation 1999;99: 2080–2084.

    Google Scholar 

  60. Maynard C, Beshansky JR, Griffith JL, et al. Influence of sex on the use of cardiac procedures in patients presenting to the emergency department. Circulation 1996;94(suppl 9):93–98.

    Google Scholar 

  61. Merz CN, Kelsey S, Pepine CJ, et al. The Women’s Ischemic Evaluation (WISE) study. J Am Coll Cardol 1999;33:1453–1461.

    CAS  Google Scholar 

  62. AHA Statement. Evidence based guidelines for cardiovascular prevention in women. Circulation 2004;109:672–693.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2005). Coronary Artery Disease. In: Coronary Heart Disease in Clinical Practice. Springer, London. https://doi.org/10.1007/1-84628-135-0_6

Download citation

  • DOI: https://doi.org/10.1007/1-84628-135-0_6

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-936-4

  • Online ISBN: 978-1-84628-135-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation